The Boeing Company (BA): Value for Money?

Page 1 of 2

Most economies around the globe are recovering, which in turn has bolstered air travel. As a result, airlines are reporting record load factors, and some countries are witnessing double digit growth for air travel. This suggests that commercial airliners would be looking to expand their fleets, which presents a bullish case for airline manufacturers.

Moreover, there has been a spike in defense contracts, and gauging from China’s aggressive military advancements, I think that trend is set to continue. This spells good news for The Boeing Company (NYSE:BA). On a global basis, Boeing is the largest manufacturer of commercial airliners (by volume), and the second-largest defense contractor, only behind Lockheed Martin Corporation (NYSE:LMT).

The Boeing Company (NYSE:BA)Defense contracts

Rising Middle East tensions, and the ever-tense relationships of India with China and Pakistan, have caused a surge in defense contracts. Lockheed Martin reported record backlog of $82 billion, even though its net income plunged by 16.7%. International defense contracts for The Boeing Company (NYSE:BA) amounted to 24% of its revenues, and in 2012, its defense order backlog surged by 41%.

Since Lockheed Martin derives more than 80% of its revenue from domestic markets, proposed cuts to the US defense budget greatly limit its growth potential. But since Boeing is rapidly capturing international defense space, and its commercial segment is setting records, I think that altogether, this somewhat hedges the risks presented by US defence budget cuts.

Commercial jets

2012 was a record year for The Boeing Company (NYSE:BA). It reclaimed the top spot of the largest commercial airplane manufacturer (by volume), and delivered 601 airplanes, its highest output since 1999, and the second highest in commercial aviation history. Its order backlog of commercial airplanes stands at a record $319 billion, and management remains optimistic about its future prospects. Boeing made a smart move by siphoning off its earnings from defense contracts into the development of its ambitious Dreamliner project. As a result, its new orders in commercial space spiked by 49%, while Airbus reported a 41% plunge in new orders.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!